News | June 21, 2026
LabGenius and LG Chem strike AI-powered deal to develop next-gen tumour-targeting antibody therapy
The collaboration is focused on overcoming a major limitation in existing cancer drugs
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
